Spotlight Correspondence
Leukemia (2003) 17, 458–460. doi:10.1038/sj.leu.2402811
Imatinib mesylate induces durable complete remission of advanced CML persisting after allogeneic bone marrow transplantation
P Vandenberghe1,2, N Boeckx3, E Ronsyn2, R Decorte4, G Verhoef5 and A Hagemeijer1
- 1Department of Human Genetics, KU Leuven, Leuven, Belgium
- 2Laboratory of Experimental Hematology, KU Leuven, Leuven, Belgium
- 3Department of Laboratory Medicine, KU Leuven, Leuven, Belgium
- 4Laboratorium voor Forensische Genetica en Moleculaire Archeologie, KU Leuven, Leuven, Belgium
- 5Department of Haematology, University Hospital Leuven, KU Leuven, Leuven, Belgium
Correspondence: P Vandenberghe, CME-UZ, Herestraat 49, 3000 Leuven, Belgium; Fax: 32 16 346063
Received 10 July 2002; Accepted 10 October 2002.
